Signal Desk · Companies

Sanofi India plans stronger push in rare disease, diabetes, haemophilia

2026-11-17 · 1 source · BusinessLine Companies

In short

Sanofi India said it wants to grow its presence in rare disease, diabetes and haemophilia. The company said about 200 trials have been done over 70 years at around 400 sites, and 18 trials are now underway.

This suggests Sanofi is continuing to invest in new medicines and treatments in these areas.

What the reporting says

Sanofi India said it looks to strengthen its presence in rare disease, diabetes and haemophilia segments. The company pointed to about 200 trials done over 70 years at 400-odd sites and said 18 trials are currently underway in future products and related segments. The remarks indicate a continued focus on expanding its pipeline and footprint in these therapeutic areas.

Why it matters

Sanofi India said it will strengthen its presence in rare disease, diabetes and haemophilia, and cited around 200 trials over 70 years across about 400 sites. It also said 18 trials are underway in future products and related segments. The update points to continued development efforts in specialty healthcare areas that matter to patients, doctors and the company’s long-term product pipeline.

Touches: Sanofi India, Healthcare, Companies

Sources